Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Autologous NK cells as adjuvant therapy after radical surgery for digestive tract cancer
ChiCTR2400092448Phase 2Not yet recruiting
- Sponsor
- The Affiliated Hospital of Qingdao University
- Start
- Nov 2024
- Modality
- Autologous CAR-T → CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies, Patient-derived iPSCs → iPSCs → Pluripotent Stem Cells → Stem Cell Therapies → Cell Therapies, CAR-NK Cells → Other Engineered Cells → Adoptive Cell Transfer → Cell Therapies
- Countries
- 1
01
Overview
Phase 2, open-label trial of troculeucel in gastrointestinal cancer (2 arms), sponsored by The Affiliated Hospital of Qingdao University. Primary endpoint: Safety. Planned start Nov 2024; status: not yet recruiting.
02
Drugs
troculeucel
03
Conditions
gastrointestinal cancer
Beyond the preview
Go deeper on ChiCTR2400092448.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2400092448.